Table 14-3.02

Primary Endpoint Analysis: Glucose (mmol/L) - Summary at Week 20 - LOCF

ANCOVA of Change from Baseline at Week 20

	Baseline ^a		Week 20		Change from Baseline		
Treatment	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	LS Mean (95% CI)b
Xanomeline High Dose	84	5.4 (1.34)	31	5.8 (1.61)	31	0.2 (1.47)	0.16 (-0.31, 0.63)
Placebo	86	5.6 (2.14)	65	5.8 (1.50)	65	0.1 (2.08)	0.09 (-0.23, 0.42)
Pairwise Comparison			Difference in LS Mean (95% CI) ^b				p-Value
Xanomeline High Dose vs. Placebo			0.07 (-0.50, 0.63)				0.822

Root Mean Squared Error of Change = 1.30

Table generated on: 2024-04-18 20:17:39 Source: [pilot3: adam-adsl; adlbc]

^a Table is based on participants who have observable data at Baseline and Week 20.

^b Based on an Analysis of covariance (ANCOVA) model with treatment and baseline value as covariates

CI = Confidence Interval, LS = Least Squares, SD = Standard Deviation